Yongda Liu
Overview
Explore the profile of Yongda Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
694
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gu D, Wang Y, Chang Y, Liu Y, Li M, Cai C, et al.
Chin Clin Oncol
. 2025 Feb;
14(1):9.
PMID: 39988337
Single-site robotic-assisted radical prostatectomy (ssRARP) has emerged as a promising advancement in urological surgery, driven by the development of advanced robotic instrumentation and single-port access technologies. Global researchers have extensively...
2.
Zheng J, Guo Q, Yue G, Dou S, Zeng X, He T, et al.
World J Urol
. 2025 Feb;
43(1):131.
PMID: 39976783
Objective: There is ongoing debate regarding whether patients with a positive urine culture (UC) need to wait for the culture to turn negative following antimicrobial treatment before undergoing percutaneous nephrolithotomy...
3.
Wang Y, Li M, Yao K, Zong Z, Chang Y, Liu Y, et al.
BJU Int
. 2025 Jan;
PMID: 39887625
No abstract available.
4.
Li Z, Cheng D, Zhu H, Karagoz M, Jiang C, Zhang S, et al.
BMC Urol
. 2024 Sep;
24(1):195.
PMID: 39242526
Background: Urolithiasis combined with ESBL-producing E. coli is often difficult to control and leads to higher postoperative infection-related complications. This study was aim to explore the efficacy and necessity for...
5.
Zhu W, Liu S, Cao J, Wang H, Liang H, Jiang K, et al.
EClinicalMedicine
. 2024 Jul;
74:102724.
PMID: 39070176
Background: Retrograde intrarenal surgery (RIRS) is the main treatments for upper urinary tract stones. The Ureteral Access Sheath (UAS) serves as a supplementary tool, facilitating direct kidney access during RIRS....
6.
Qu W, Fu C, Han W, Luo H, Quan J, Chen L, et al.
Eur J Cancer
. 2024 May;
205:114096.
PMID: 38772302
Background: MRG002 is a novel HER2-targeted antibody-drug conjugate being investigated in the MRG002-006 trial to evaluate the efficacy and safety in HER2-positive urothelial carcinoma patients. Methods: This is an open-label,...
7.
Zhong W, Osther P, Pearle M, Choong S, Mazzon G, Zhu W, et al.
World J Urol
. 2024 Mar;
42(1):189.
PMID: 38526675
Background: The stone burden based management strategy reported in the guidelines published by different associations is well known for a long time. Staghorn calculi, representing the largest burden and most...
8.
Zhao R, Xia Z, Ke M, Lv J, Zhong H, He Y, et al.
Eur J Nucl Med Mol Imaging
. 2024 Jan;
51(7):2124-2133.
PMID: 38285206
Purpose: This paper discusses the optimization of pharmacokinetic modelling and alternate simplified quantification method for [F]AlF-P16-093, a novel tracer for in vivo imaging of prostate cancer. Methods: Dynamic PET/CT scans...
9.
Zhao R, Ke M, Lv J, Liu S, Liu Y, Zhang J, et al.
Eur J Nucl Med Mol Imaging
. 2024 Jan;
51(6):1753-1762.
PMID: 38212531
Purpose: This is a first-in-human study to evaluate the radiation dosimetry of a new prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical, [F]AlF-P16-093, and also initial investigation of its ability to detect PSMA-positive...
10.
He T, Zhang Q, Xu P, Tao W, Lin F, Liu R, et al.
Mol Cancer
. 2023 Jul;
22(1):117.
PMID: 37481520
Background: The encapsulation of circular RNAs (circRNAs) into extracellular vesicles (EVs) enables their involvement in intercellular communication and exerts an influence on the malignant advancement of various tumors. However, the...